Market Cap (In USD)
45.06 Million
Revenue (In USD)
-
Net Income (In USD)
-23.51 Million
Avg. Volume
48.37 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.55-6.97
- PE
- -
- EPS
- -
- Beta Value
- 1.218
- ISIN
- US29415J1060
- CUSIP
- 29415J106
- CIK
- 1661053
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Mr. Robert A. Berman
- Employee Count
- -
- Website
- https://www.envveno.com
- Ipo Date
- 2018-05-31
- Details
- enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
More Stocks
-
GRN
-
301020
-
NNVCNanoViricides, Inc.
NNVC
-
GEVI
-
TSG
-
MANN
-
IPU
-
0QLQYpsomed Holding AG
0QLQ